The adenovirus (Ad) is widely used as a vaccine because of its ability to induce a cellular and humoral immune response. In addition, human clinical trials have validated the safety and efficacy of Ad as a vaccine vector. The traditional approach for employing the adenovirus as vaccine is to configure the antigen genes into the expression cassette of the Ad genome. An alternative method for inducing an immune response is the "capsid-incorporation" strategy. This strategy is based upon the incorporation of proteins or peptides into the capsid proteins. This review will focus on the established uses of this approach as well as highlighting the new developments regarding the capsid-incorporation strategy.

Original languageEnglish
Pages (from-to)5446-5453
Number of pages8
JournalMolecular Pharmaceutics
Issue number12
StatePublished - Dec 3 2018


  • adenovirus
  • antigen
  • capsid
  • capsid incorporation
  • epitope display
  • vaccine
  • virus


Dive into the research topics of 'Capsid-Incorporation Strategy to Display Antigens for an Alternative Adenoviral Vector Vaccine Approach'. Together they form a unique fingerprint.

Cite this